Weekly Recap: Phase 3 misses endpoint and Q4 loss narrows, cash needed

Rafael Holdings, Inc. Class B (NYSE:RFL) said Trappsol Cyclo’s Phase 3 trial missed its primary endpoint, but a prespecified subgroup showed significant benefit; its remibetadex application is under FDA review after an October submission. The company narrowed its fiscal Q4 loss to $9.2 million but warned it needs financing, with $22.1 million in cash at July 31.

Previous Week Recap

• Trial Misses Primary Endpoint: Rafael Holdings (RFL) said Trappsol Cyclo’s Phase 3 trial missed its primary endpoint, though a prespecified subgroup showed significant benefit. Its New Drug Application remains under FDA review.
  • 
  Quartr
• Q4 Loss Narrows, Financing Needed: Rafael Holdings (RFL) cut its fiscal Q4 2026 loss to $9.2 million, or $0.18 per share. It had $22.1 million in cash at July 31 and warned it needs financing to continue.
  • 
  • 
  2 źródła
• Remibetadex Application Submitted: Rafael Holdings, Inc. Class B (RFL) said it submitted a new drug application for remibetadex in October 2026.
  • 
  TradingView